Sheppard Riva - 21 May 2025 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 May 2025, 17:57:37 UTC
Prior SEC filing
05 Dec 2024
Next SEC filing
10 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Riva Sheppard

Key filing fact

Sheppard Riva filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 22 May 2025.

Key facts

  • This page summarizes Sheppard Riva's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 22 May 2025, 17:57.

Change

  • Previous filing in this sequence was filed on 05 Dec 2024.
  • Current net transaction value: +$13,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001064900 Primary reporting owner

RIVA SHEPPARD

Relationship
Co-Chief Executive Officer, Director, 10%+ Owner
Address
C/O 225 LONG AVENUE, HILLSIDE
Signature
/s/ Riva Sheppard
Signature date
22 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBP transaction

Common Stock

Award

Transaction value
$13,000
Shares
+144,445
Change %
+11%
Price
$0.0900
Shares after
1,473,467
Date
21 May 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-144,445
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
144,445
Exercise price
$0.0900
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

144,445 common stock shares acquired upon exercise of stock option grant dated June 2, 2015.

Footnote F2

81,945 of the options became exercisable on June 2, 2015 and the remaining 62,500 became exercisable in three equal annual installments beginning on June 2, 2016.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .